泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

未开盘 09-24 16:08:31

45.100

-1.660

-3.55%

最高47.200	最低45.000	成交量71.29万
今开46.300	昨收46.760	日振幅4.70%
总市值388.31亿	流通市值55.53亿	总股本8.61亿
成交额3,276万	换手率0.58%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":45.1,"timestamp":1790237311007,"preClose":46.76,"halted":0,"volume":712908,"delay":0,"changeRate":-0.035500427715996506,"floatShares":123124800,"shares":861000000,"eps":1.214392258044278,"marketStatus":"未开盘","change":-1.66,"latestTime":"09-24 16:08:31","open":46.3,"high":47.2,"low":45,"amount":32757530,"amplitude":0.047049,"askPrice":45.2,"askSize":300,"bidPrice":45.1,"bidSize":3300,"shortable":3,"etf":0,"ttmEps":0.12404549841976897,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790299800000},"marketStatusCode":0,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":46.76,"dividendRate":0.003228,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.4269959004557284,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":56.81,"timestamp":1790233200000,"preClose":58.5,"halted":0,"volume":7923300,"delay":0,"premium":"-32.01"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2669469864","title":"泰格医药（300347）披露2026年第三次临时股东会等会议决议公告，9月24日股价下跌2.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469864?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242580,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，泰格医药报收于56.81元，较前一交易日下跌2.89%，最新总市值为489.15亿元。公司于近日披露《2026年第三次临时股东会、2026年第三次A股类别股东会议及2026年第三次H股类别股东会议决议的公告》。会议表决结果合法有效，无否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","300347","BK0174","BK0028","03347","BK0077","LU1146622755.USD","LU1820825898.SGD","BK1141","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146234888","title":"泰格医药：摩根大通增持，好仓比例升至20.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146234888","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146234888?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:25","pubTimestamp":1790241957,"startTime":"0","endTime":"0","summary":"2026年9月21日，摩根大通依据证券借贷协议收回借出的102.81万股泰格医药（03347）H股股份，好仓持股及比例相应增加。该笔交易属收回借出股份，并非在联交所公开市场直接买卖。摩根大通此次增持前持有泰格医药好仓2540.03万股，占比20.62%；增持后持股量为2540.46万股，好仓比例升至20.63%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669466136","title":"摩根大通在泰格医药的H股好仓比例上升0.01%至20.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669466136","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669466136?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:18","pubTimestamp":1790241480,"startTime":"0","endTime":"0","summary":"南财智讯9月24日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在泰格医药的H股好仓（L）比例于9月21日从20.62%上升至20.63%。同时淡仓（S）比例从0.73%升至0.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883773851.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883773851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1820825898.SGD","LU1146622755.USD","PGF","BK0174","BK1576","BK4582","300347","BK0077","BK0028","BK1141","BK0216","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","LU2039709279.SGD","688428","09969","SG9999002562.SGD","06990","LU0456846285.SGD","LU0516422366.SGD","LU0516423174.USD","LU1242518931.SGD","LU1303224171.USD","161726","LU1961090484.USD","LU0828237510.HKD","09688","HK0000306701.USD","02269","LU0348825331.USD","XBI","LU0856984785.SGD","BK1583","LU0348783233.USD","LU0540923850.HKD","LU1770034418.SGD","BK1515","01877","LU2399975544.HKD","LU1880383366.USD","399441","LU3063872942.SGD","03347","02162","LU0140636845.USD","02268","LU2328871848.SGD","KURE","BK1576","01548","09995","LU0348766576.USD","LU1719994722.HKD","BK4581","LU1242518857.USD","LU0561508036.HKD","SG9999014674.SGD","BK1141","SG9999002463.SGD","09926","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132753197","title":"泰格医药（03347）股东大会全部议案获高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1132753197","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132753197?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:41","pubTimestamp":1790174474,"startTime":"0","endTime":"0","summary":"2026年9月23日，泰格医药在杭州召开2026年第三次临时股东大会、第三次A股类别股东会议及第三次H股类别股东会议。公告显示，会议就7项议案进行表决，所有议案均获股东高比例赞成并正式通过。公司将按相关监管要求，发布回购A股决议案表决结果的具体公告，并开展获批事项的后续工作。泰格医药表示，所有议案获高比例通过，为公司后续资本运作及股权激励实施提供了法定依据。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100457115","title":"泰格医药自查：激励计划前半年未现内幕交易 124名激励对象交易合规","url":"https://stock-news.laohu8.com/highlight/detail?id=1100457115","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100457115?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:45","pubTimestamp":1790171155,"startTime":"0","endTime":"0","summary":"2026年9月23日，泰格医药发布《关于2026年A股限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告》。公司于2026年8月28日召开第六届董事会第二次会议，审议通过《2026年A股限制性股票激励计划（草案）》及其摘要，并于2026年8月29日首次公开披露相关信息。根据《上市公司股权激励管理办法》等规定，泰格医药就激励计划首次公开披露前6个月内的股票交易情况展开自查。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108818565","title":"泰格医药（03347）拟注销588.38万股回购股份并下调注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1108818565","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108818565?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:45","pubTimestamp":1790171154,"startTime":"0","endTime":"0","summary":"2026年9月23日，泰格医药公告称，公司计划将2024年4月30日至2025年4月30日期间已回购的5,883,780股股份由“用于后续实施股权激励或员工持股”调整为“注销以减少注册资本”。\\n\\n注销完成后，公司股份总数将由861,026,050股减少至855,142,270股。\\n\\n该议案已分别于2026年8月28日召开的第六届董事会第二次会议，以及2026年9月23日召开的2026年第三次临时股东大会、2026年第三次A股类别股东会议和2026年第三次H股类别股东会议审议通过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141573138","title":"泰格医药于港交所发布海外监管公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1141573138","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141573138?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:45","pubTimestamp":1790171138,"startTime":"0","endTime":"0","summary":"2026年9月23日，泰格医药在香港联合交易所有限公司网站发布海外监管公告。公告称，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容概不负责，并不对其准确性或完整性作出任何声明，且明确表示概不承担因依赖该等内容而产生的任何损失责任。本次披露的文件已于深圳证券交易所网站同步刊登，供投资者参考。泰格医药强调，此次公告的发布符合香港联交所证券上市规则第13.10B条的相关要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172529707","title":"泰格医药修订公司章程：注册资本降至85,514.2270万元并调整董事会及管理层设置","url":"https://stock-news.laohu8.com/highlight/detail?id=1172529707","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172529707?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:36","pubTimestamp":1790170564,"startTime":"0","endTime":"0","summary":"2026年9月23日，泰格医药发布海外监管公告，披露公司章程主要条款修订情况，涉及注册资本、股本结构及公司治理架构等多项内容。现将核心数据摘录如下：。注册资本由人民币86,102.6050万元调整为人民币85,514.2270万元。已发行股份数由86,102.6050万股下调至85,514.2270万股。调整前，境内上市内资股（A股）为737,901,250股，占公司总股本约85.70%；境外上市外资股（H股）为123,124,800股，占约14.30%。公告称，上述章程修订已在深圳证券交易所网站公布，供投资者查阅。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197273318","title":"泰格医药（03347）多项议案获高票通过 完成2026年第三次临时股东大会决议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197273318","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197273318?lang=zh_cn&edition=full","pubTime":"2026-09-23 21:35","pubTimestamp":1790170541,"startTime":"0","endTime":"0","summary":"泰格医药9月23日公告，2026年第三次临时股东大会及同期召开的A股、H股类别股东会议全部议案获高比例通过。本次股东大会于2026年9月23日15:00在杭州市滨江区陆家潭街508号六楼会议室举行，并同步提供网络投票。其中，A股股东441名，代表股份392,676,971股；H股股东1名，代表股份52,258,858股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","03347","02359","03759","06622","06978","06996","00241","09606","09688","09966","06606","09995","02137","06618","02268","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150983","title":"泰格医药子公司方达医药顺利通过沙特SFDA现场核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150983","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669150983?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:51","pubTimestamp":1789987860,"startTime":"0","endTime":"0","summary":"近日，由方达医药提供临床运营及生物分析一体化全包服务的一项肿瘤药物临床研究，顺利通过沙特食品药品监督管理局(Saudi Food and Drug Authority,SFDA)现场核查，为产品海外注册及市场拓展 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680134776.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680134776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0216","300347","BK1161","BK0028","BK1574","BK1576","09939","LU1146622755.USD","BK1583","LU1820825898.SGD","BK0077","159938","BK0174","BK1141","03347","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137566320","title":"泰格医药（03347）完成2026年A股限制性股票激励计划首次授予名单公示及核查","url":"https://stock-news.laohu8.com/highlight/detail?id=1137566320","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137566320?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:06","pubTimestamp":1789985172,"startTime":"0","endTime":"0","summary":"泰格医药9月21日披露海外监管公告称，公司已完成《2026年A股限制性股票激励计划（草案）》首次授予激励对象名单的内部公示及核查工作。根据公告，公司于2026年9月11日至2026年9月20日期间在内部OA系统公示拟首次授予的激励对象姓名及职务，公示期为10天。公司表示，此次核查结果表明拟授予激励对象全部符合相关规定，后续将按程序推进2026年A股限制性股票激励计划的实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159039615","title":"泰格医药（03347）完成股权激励计划自查：各项指标均符合监管要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1159039615","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159039615?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:05","pubTimestamp":1789985144,"startTime":"0","endTime":"0","summary":"2026年9月21日，杭州泰格医药科技股份有限公司公布《创业板上市公司股权激励计划自查表（更新）》，就公司实施股权激励的合规性、披露完整性及审议程序等41项具体条款进行了自查。结果显示，公司在财务合规、激励对象资格、激励规模及期限设置等方面均符合监管要求，未发现禁止实施股权激励的情形。泰格医药表示，将继续严格遵循监管规定，落实信息披露义务，推动股权激励计划顺利实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669535961","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669535961","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669535961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:03","pubTimestamp":1789974221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规划涵盖创新药、创新医疗器械、人工智能驱动药物发现，以及CDMO/CRO等技术领域，显示政策正对整条价值链作出广泛支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422366.SGD","LU1242518857.USD","02269","06990","LU0029874061.USD","BK4588","LNGR","LU3063872942.SGD","MEDX","RSPH","LU1807302812.USD","KURE","IEIH","GDOC","LGHT","LU1226287875.USD","159992","HK0000165453.HKD","LU0455707207.USD","01276","LU1244550494.USD","FTXO","LU0067412154.USD","BK4566","IYF","LU2417539215.USD","03347","TFNS","PTH","SG9999002463.SGD","06978","LU0516422440.USD","LU0359201885.HKD","LU1152091168.USD","LU0456827905.SGD","HART","BK1576","01801","AGNG","LU1366192091.USD","IE00B543WZ88.USD","IBBQ","LU0029874905.USD","LU0128525689.USD","159883","09996","LU0561508036.HKD","MDEV","LU1242518931.SGD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","02269","02162","06990","09969","01877","03347","02359","09926","02268","02696","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0348766576.USD","BK1161","03347","LU1880383366.USD","LU3063872942.SGD","LU0561508036.HKD","603127","HK0000306701.USD","LU0029874905.USD","LU0359202008.SGD","BK1141","LU0540923850.HKD","LU1242518857.USD","BK1583","LU1794554557.SGD","LU0043850808.USD","LU0516422440.USD","LU0516422366.SGD","BK1515","LU0588546209.SGD","02359","LU0516422952.EUR","01548","LU0348825331.USD","LU0051755006.USD","BK1589","09939","03759","HK0000320223.HKD","06127","LU0307460666.USD","LU2242644610.SGD","CXO","159938","LU2125910500.SGD","SG9999002463.SGD","01873","LU0516423091.SGD","KURE","02269","LU0359201612.USD","LU0456846285.SGD","LU0052750758.USD","LU0516423174.USD","WX","LU0039217434.USD","BK1610","LU0029874061.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128522744.USD","06990","LU0244354667.USD","399441","LU0634319403.HKD","LU0326950275.SGD","02268","LU0463099449.HKD","BK1515","LU0979878070.USD","LU1961090484.USD","09969","LU0348766576.USD","02696","161726","06160","LU0320764243.SGD","LU0561508036.HKD","LU2045819591.USD","09926","LU1880383366.USD","LU2476274720.SGD","XBI","02162","LU0196878994.USD","01877","02359","LU0052750758.USD","LU0348767384.USD","01548","HK0000165453.HKD","LU0540923850.HKD","LU0029874905.USD","LU0320764599.SGD","03347","LU0327786744.USD","LU1188198961.HKD","09995","LU0456827905.SGD","KURE","LU2242644610.SGD","BK4588","LU0348784397.USD","LU1303224171.USD","BK1610","LU0516422952.EUR","BK1588","LU2488822045.USD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668117179","title":"七年迟报权益变动引监管倒查，CRO 龙头主业回暖净利润却亏 4.13 亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668117179","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668117179?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:53","pubTimestamp":1789699985,"startTime":"0","endTime":"0","summary":"2026年9月，国内临床CRO龙头泰格医药（300347.SZ/03347.HK）公告，公司实际控制人叶小平、曹晓春因两起历史持股变动未及时披露收到监管文件。其中2019年9月的一起被认定构成信息披露违法，拟对二人给予警告并合计罚款100万元、各承担50万元；2022年12月的一起则被出具警示函并记入诚信档案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878421992.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878421992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300347","BK1141","BK1576","BK0077","LU1146622755.USD","LU1820825898.SGD","BK0174","BK0216","BK1583","03347","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0456846285.SGD","LU0051755006.USD","LU0828237510.HKD","01548","LU0039217434.USD","LU0181495838.USD","LU0588546209.SGD","KURE","LU0561508036.HKD","02359","LU0634319403.HKD","06127","LU0228659784.USD","LU3063872942.SGD","LU1251922891.USD","LU1880383366.USD","LU0856984785.SGD","LU1719994722.HKD","LU2039709279.SGD","WX","LU1242518857.USD","06821","LU0320764243.SGD","LU0359202008.SGD","BK0216","01873","LU0320764599.SGD","SG9999002562.SGD","03347","LU0348735423.USD","LU1242518931.SGD","02269","LU1688375341.USD","603127","CXO","LU0052750758.USD","LU0348827113.USD","BK1161","BK1521","LU0029874905.USD","LU2242644610.SGD","06160","BK1588","LU0348825331.USD","LU0469268626.HKD","BK1610","LU0029874061.USD","LU0516423174.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.3273},{"period":"6month","weight":0.0939},{"period":"1year","weight":-0.0521},{"period":"ytd","weight":0.0651}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家主要从事为新药研发提供临床试验全过程专业服务的中国公司。该公司提供服务主要包括临床试验技术服务和临床试验相关及实验室服务。临床试验技术服务提供创新药物、仿制药及医疗器械临床试验运营服务以及与临床试验直接相关的配套服务，包括临床运营、临床药理、注册与法规事务、科学事务等服务。临床试验相关及实验室服务提供在药物开发过程中的相关及实验室服务，包括数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室等服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.032258},{"month":2,"riseRate":0.5,"avgChangeRate":0.003409},{"month":3,"riseRate":0.5,"avgChangeRate":-0.032695},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.051086},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.017912},{"month":6,"riseRate":0.666667,"avgChangeRate":0.042051},{"month":7,"riseRate":0.666667,"avgChangeRate":0.080461},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.061347},{"month":9,"riseRate":0.428571,"avgChangeRate":0.041157},{"month":10,"riseRate":0.5,"avgChangeRate":-0.025938},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.001369},{"month":12,"riseRate":0.5,"avgChangeRate":0.041242}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}